Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...
Zymeworks (NASDAQ:ZYME) said it has achieved a $14M cash research milestone through its collaboration with GSK (GSK). Under ...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...
Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...
Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics ...
Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms ...
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...
Zymeworks Inc., a clinical-stage biotechnology company focused on developing innovative biotherapeutics for challenging diseases such as cancer, inflammation, and autoimmune disorders, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results